KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Edwards Lifesciences (EW) Deferred Taxes (2016 - 2025)

Historic Deferred Taxes for Edwards Lifesciences (EW) over the last 17 years, with Q3 2025 value amounting to $18.0 million.

  • Edwards Lifesciences' Deferred Taxes fell 8536.59% to $18.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $161.7 million, marking a year-over-year decrease of 4887.76%. This contributed to the annual value of $323.4 million for FY2024, which is 1885.34% up from last year.
  • According to the latest figures from Q3 2025, Edwards Lifesciences' Deferred Taxes is $18.0 million, which was down 8536.59% from $20.9 million recorded in Q2 2025.
  • In the past 5 years, Edwards Lifesciences' Deferred Taxes registered a high of $123.0 million during Q3 2024, and its lowest value of -$10.8 million during Q1 2021.
  • Moreover, its 5-year median value for Deferred Taxes was $46.3 million (2022), whereas its average is $50.2 million.
  • In the last 5 years, Edwards Lifesciences' Deferred Taxes crashed by 20000.0% in 2021 and then surged by 128717.95% in 2022.
  • Quarter analysis of 5 years shows Edwards Lifesciences' Deferred Taxes stood at $61.5 million in 2021, then soared by 72.03% to $105.8 million in 2022, then decreased by 13.61% to $91.4 million in 2023, then increased by 7.77% to $98.5 million in 2024, then crashed by 81.73% to $18.0 million in 2025.
  • Its Deferred Taxes stands at $18.0 million for Q3 2025, versus $20.9 million for Q2 2025 and $24.3 million for Q1 2025.